Abstract
A drug may fail or raise concerns that must be addressed in later-phase trials because of an unacceptable toxicity profile, even if the drug meets expectations for efficacy. The problem could be due to the late onset of unacceptable toxicities that were not observed in early-phase trials. We explore methodologies to find appropriate doses in situations where a drug meets the primary efficacy objective but concerns about toxicity remain. In this manuscript, we propose a general framework to design a good phase IV trial that is designed to optimize the treatment regimen. In the first step, we learn from the existing data about the dose-response and dose-toxicity relationships and further to explore and establish the relationship using a statistical model. Noting the limitations of the exploratory analyses, these analyses are not sufficient to allow us to make definitive conclusions. However, the prediction obtained from the model, either estimated efficacy metrics or safety parameters for some doses, can be incorporated in the design of the phase IV trial. In the second step, we further propose and compare design options, including options that could effectively incorporate information from these exploratory analyses, for clinical trials to find optimal doses, including trials to fulfill postmarketing commitments or requirements.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Nie L, Rubin E, Mehrotra N, Pinheiro J, Fernandes L, Roy A, et al. Rendering the 3 + 3 design to rest: more efficient approaches to oncology dose-finding trials in the era of targeted therapy. Clin Cancer Res. 2016;22:2623–2629.
ASCO post report, FDA approves revised prescribing information for Ponatinib, authorizes resumption of drug sales and distribution. ASCO post, 2013. http://www.ascopost.com/ViewNews.aspx?nid=11871.
Cortes JE, Kim DW, Pinilla-IbarZ J, Le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of Ponatinib in Philadelphia chromosome-positive leukemias. N Eng J Med. 2013;369:1783–1796.
Cortes JE, Kantrrjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Eng J Med. 2012;367:2075–2088.
Buyes M. Randomized designs for early trials of new cancer treatments. Drug Inform J. 2000;34:387–396.
Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11:550–560.
Joseph L, Du Berger R, Belisle P. Bayesian and mixed Bayesian/likelihood criteria for sample size determination. Stat Med. 1997;16(7):769–781.
Thall PF, Russell KT. A strategy for dose finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials. Biometrics. 1998;54:251–264.
Ivanova A. A new dose-finding design for bivariate outcomes. Biometrics. 2003;59:1001–1007
Thall P F, Cook JD. Dose-finding based on efficacy toxicity trade-offs. Biometrics. 2004;60:684–693.
Wang K, Ivanova A. Two-dimensional dose finding in discrete dose space. Biometrics. 2005;61(1):217–222.
Yin G, Li Y, Ji Y. Bayesian dose-finding in phase I/II trials using toxicity and efficacy odds ratio. Biometrics. 2006;62:777–784.
Yuan Y, Yin G. Bayesian dose finding by jointly modelling toxicity and efficacy as time-to-event outcomes. J R Stat Soc Ser C. 2009;58:719–736.
Bekele BN, Ji Y, Shen Y, Thall PF. Monitoring late-onset toxicity in phase I trials using predicted risks. Biostatistics. 2008;9:442–457.
Liu S, Yin G, Yuan Y. Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity. Ann Appl Stat. 2013;7(4):1837.
Yuan Y, Yin G. Robust EM continual reassessment method in oncology dose finding. J Am Stat Assoc. 2011;106:818–831.
Ibrahim JG, Chen MH. Power prior distributions for regression models. Stat Sci. 2000;15(1):46–60.
Hobbs BP, Carlin BP, Mandrekar SJ, Sargent DJ. Hierarchical commensurate and power prior models for adaptive incorporation of historical information in clinical trials. Biometrics. 2011;67(3):1047–1056.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nie, L., Lee, K.Y., Verdun, N. et al. Dose Finding in Late-Phase Drug Development. Ther Innov Regul Sci 51, 738–743 (2017). https://doi.org/10.1177/2168479017709297
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1177/2168479017709297